INM Overview

Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.

Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.

Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.

Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.

NVIDIA's Strong Performance: NVIDIA Corp's shares rose 5.2% in pre-market trading after reporting a 62% year-over-year revenue increase to $57.0 billion for Q3, surpassing expectations with a strong revenue forecast for the current quarter.

Notable Gainers: Several stocks saw significant pre-market gains, including Sonder Holdings Inc (+138.8%), Inspire Veterinary Partners Inc (+60.3%), and Cerence Inc (+29.2%), following positive financial results or forecasts.

Major Losers: WeShop Holdings Limited experienced a sharp decline of 38.8% in pre-market trading after a previous surge, while other notable losers included Brera Holdings PLC (-35.5%) and Meihua International Medical Tech Co Ltd (-23.8%).

Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting better-than-expected financial results while others faced significant declines.

Stock Performance: InMed Pharmaceuticals Inc. shares rose 21.98% in after-hours trading to $1.50, despite a 15.75% drop during the regular session, closing at $1.23.

Research Milestone: The company successfully completed pharmacokinetic studies for its Alzheimer’s candidate INM-901 in large animal models, demonstrating strong bioavailability and therapeutic exposure.

Regulatory Plans: InMed is preparing for Investigational New Drug (IND) submission by conducting dose-ranging studies and a pre-IND meeting with the FDA, alongside additional development for production scaling.

Financial Overview: As of September 30, InMed reported $9.3 million in cash, sufficient to fund operations into Q4 2026, although its stock has declined 74.38% this year, with a market cap of $3.45 million.

Event Announcement: InMed Pharmaceuticals Inc. will present at the Life Sciences Virtual Investor Forum on September 18, 2025, where CEO Eric A. Adams will discuss updates on the company's drug pipeline, including recent data on INM-901 for Alzheimer's treatment.

Interactive Participation: The event will allow real-time questions from investors, with an archived webcast available for those unable to attend live. Pre-registration is recommended for a smoother experience.

Event Announcement: The Life Science Virtual Investor Forum is scheduled for September 18, 2025, co-hosted by Zacks SCR, inviting individual and institutional investors to attend presentations and one-on-one meetings with company management.

Participation Details: Investors are encouraged to pre-register and perform an online system check for a smoother experience, with no cost to attend live presentations or schedule meetings.

Stock Performance: Cognition Therapeutics Inc (CGTX) saw a significant stock increase of 20.82% during regular trading hours, followed by an additional 12.10% rise in after-hours trading, reaching $0.45.

Drug Trial Success: The surge in stock price is linked to promising results from its Alzheimer's drug, Zervimesine, which achieved a 95% efficacy rate in its Phase 2 trial and reached a 50% enrollment milestone.